The lung surfactant market is a distinct area within the broader respiratory therapeutics landscape, focusing on a critical therapy for neonatal and adult respiratory conditions. The lung surfactant market is projected to grow from USD 3.72 billion in 2025 to USD 6.49 billion by 2035, at a CAGR of 5.18%. This growth is underpinned by consistent demand and ongoing research.

The market is segmented by indication, drug type, route of administration, and end-user. The primary indication is neonatal respiratory distress syndrome (RDS), which represents the largest segment. Other applications include treating respiratory infections and other pulmonary conditions. Leading products include animal-derived surfactants like Poractant alfa and Beractant, as well as synthetic options like Lucinactant. Intratracheal administration is the most common route, typically performed in a hospital setting.

Key players in the global lung surfactant market include major pharmaceutical companies like AbbVie, AstraZeneca, Boehringer Ingelheim, and Novartis. Other notable contributors include specialized firms such as Chiesi Farmaceutici, ONY Biotech, and Lyomark Pharma. The competitive landscape is defined by a mix of established players and specialty manufacturers, with a focus on developing more effective and easier-to-administer formulations. For a detailed breakdown of market share and competitive strategies, a review of the lung surfactant market is invaluable.